TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28961661
Drug: Blister packing
Normalized name: Blister Armour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blister packing medications (BP)
Study: 22781166
Drug: Full cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full cognitive behaviour therapy (CBT)
Study: 22781166
Drug: Partial therapy
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial therapy (attending sessions but not proceeding beyond engagement and assessment strategies)
Study: 22781166
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (not attending sessions)
Study: 21780853
Drug: Repaglinide plus
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide plus metformin 1 mg/500 mg t.i.d. (maximum dose, 4 mg/500 mg t.i.d.)
Study: 21780853
Drug: Repaglinide 1
Normalized name: repaglinide 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 1 mg t.i.d. (maximum dose, 4 mg t.i.d.)
Study: 21780853
Drug: Repaglinide plus
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide plus metformin
Study: 18582181
Drug: Methylphenidate (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.4 mg/kg)
Study: 18582181
Drug: Methylphenidate (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.8 mg/kg)
Study: 18582181
Drug: Methylphenidate (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (1.5 mg/kg)
Study: 2880689
Drug: Indenolol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indenolol (30 to 120 mg)
Study: 28397533
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy adherence assessment
Study: 18426627
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral administration of ramosetron 0.1 mg (Group C)
Study: 18426627
Drug: Single prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single prophylactic intravenous injection of ramosetron 0.1 mg (Group B)
Study: 17175489
Drug: Cetrorelix 0.2
Normalized name: cetrorelix 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix 0.2 mg/day (Group 1)
Study: 17175489
Drug: Cetrorelix 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix 0.15 mg/day (Group 2)
Study: 14561020
Drug: HandiHaler (tiotropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: HandiHaler (tiotropium 18 microg daily)
Study: 11127249
Drug: Quinine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (oral dose)
Study: 8865956
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin (200 IU three times a week)
Study: 8865956
Drug: Biological markers
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological markers of alcohol consumption
Study: 31029516
Drug: Dukoral® oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dukoral® oral cholera vaccine (administered at baseline and day 14)
Study: 31029516
Drug: Dukoral® oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dukoral® oral cholera vaccine (administered at baseline and day 14) in P/CNI group
Study: 31029516
Drug: Dukoral® oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dukoral® oral cholera vaccine (administered at baseline and day 14) in P/MMF group
Study: 28614627
Drug: Multimodal cachexia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal cachexia intervention (n‐3 polyunsaturated fatty acid nutritional supplements, exercise, and anti‐inflammatory medication: celecoxib)
Study: 22231004
Drug: Toothbrushing with
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toothbrushing with 0.12% chlorhexidine gluconate (Periogard®) mouthrinses twice a week
Study: 11831621
Drug: Successful treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful treatment strategies for atheroma
Study: 9758029
Drug: SUPPORT intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUPPORT intervention (n=386): specially trained nurses providing extra time to explain prognoses and treatments
Study: 8641505
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative medical treatment
Study: 6795050
Drug: Acute pentagastrin
Normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute pentagastrin injection in normal male subjects
Study: 6795050
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of pentagastrin
Study: 6795050
Drug: Intragastric administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric administration of a calcium chloride solution
Study: 29065142
Drug: MVA-B boost
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-B boost (fourth dose)
Study: 20145345
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg/day) with clopidogrel (75 mg/day)
Study: 20145345
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/day) alone (placebo)
Study: 17919378
Drug: Cattle encephalon
Normalized name: Oryctolagus cuniculus diencephalon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cattle encephalon glycoside and ignotin injection (20 ml after induction of anesthesia)
Study: 15673424
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose solution
Study: 7963387
Drug: Interpleural block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpleural block (IPB) with 10 ml of 1% lidocaine
Study: 7963387
Drug: Epidural block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural block (EB) with 10 ml of 1% lidocaine
Study: 3298360
Drug: Intravenous APSAC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous APSAC, 30 mg (n = 16)
Study: 27629372
Drug: Medicine (medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine (medicine group)
Study: 24961325
Drug: Neovasculogen (plasmid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neovasculogen (plasmid genetic construction containing human gene VEGF165) at a course dose of 2.4 mg
Study: 24961325
Drug: Conventional vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional vascular therapy
Study: 22429362
Drug: Terlipressin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin infusion at 1.0‐4.0 μg/kg per h
Study: 30079635
Drug: Terlipressin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin infusion
Study: 22429362
Drug: Terlipressin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin infusion >2.0 μg/kg per h during the preanhepatic phase
Study: 22429362
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (generally accepted inotropic and vasopressor agents)
Study: 18757528
Drug: Psychotropic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medication
Study: 16311183
Drug: Sublingual (SL)
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual (SL) liquid buprenorphine
Study: 16311183
Drug: Sublingual (SL)
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual (SL) tablet buprenorphine
Study: 12425406
Drug: Fluid augmentation
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid augmentation during the first 36 hours after surgery
Study: 8678366
Drug: Cancer that
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer that has spread through the capsule
Study: 1892146
Drug: Ofloxacin, 400
Normalized name: Ofloxacin, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin, 400 mg every 12 hours, administered orally or by nasogastric tube
Study: 1892146
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (individual investigator's best selection of therapy administered parenterally)
Study: 6660930
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intracervical prostaglandin E2 (PGE2) gel
Study: 6660930
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intracervical prostaglandin E2 (PGE2) gel followed by i.v. oxytocin
Study: 6660930
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intracervical prostaglandin E2 (PGE2) gel followed by another dose of PGE2-gel and subsequent i.v. oxytocin
Study: 27993166
Drug: mHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth intervention (twice-weekly voice messages about diabetes prevention and control)
Study: 27993166
Drug: Participatory community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participatory community group intervention (monthly group meetings for men and women to address diabetes issues)
Study: 22188557
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (2.5 g)
Study: 22188557
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (5.0 g)
Study: 22188557
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (2.5 g) with t-shirt
Study: 22188557
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (any dose) with washing
Study: 22188557
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (upper arms/shoulders application site)
Study: 22188557
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (any dose)
Study: 7614530
Drug: NIF CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIF CC 30 mg daily
Study: 7614530
Drug: NIF GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIF GITS 30 mg daily
Study: 7758054
Drug: NIF GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIF GITS 60 mg daily
Study: 7758054
Drug: NIF CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIF CC 60 mg daily
Study: 23686821
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA) 40mg administered subcutaneously three times weekly (tiw) for 12 months
Study: 10789885
Drug: Amitriptyline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (100 mg)
Study: 9323616
Drug: RV3 rotavirus
Normalized name: ROTAVIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV3 rotavirus vaccine (1 mL oral dose, 6.5 x 10(5) FFU/mL)
Study: 7870966
Drug: Alprazolam (APZ)
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam (APZ) 0.003 mg/kg
Study: 7870966
Drug: Alprazolam (APZ)
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam (APZ) 0.007 mg/kg
Study: 7870966
Drug: Alprazolam (APZ)
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam (APZ) 0.02 mg/kg
Study: 29949873
Drug: Synbiotics (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics (2.5 g once daily for 12 weeks)
Study: 27926473
Drug: 75g oral
Normalized name: Mesalamine 0.375g Oral capsule, biphasic release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75g oral glucose load (OGTT)
Study: 22545251
Drug: Implant-supported crowns
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-supported crowns
Study: 18234565
Drug: Non-adrenergic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adrenergic treatment (control group)
Study: 10368449
Drug: Anthracycline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline treatment (cumulative doses between 45 and 1150 mg/m2, median 270 mg/m2)
Study: 2050093
Drug: Wholemeal bread
Normalized name: Wholemeal bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wholemeal bread (50 g available carbohydrate)
Study: 23656707
Drug: White bread
Normalized name: White bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: White bread (50 g available carbohydrate)
Study: 2050093
Drug: Grained wholemeal
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grained wholemeal rye bread (50 g available carbohydrate)
Study: 2050093
Drug: Grained wholemeal
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grained wholemeal rye bread with 40% dried figs (50 g available carbohydrate)
Study: 7862884
Drug: Fluvoxamine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (150 mg daily)
Study: 25205320
Drug: Probiotic consortium
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic consortium (Lab4) plus 50 mg vitamin C
Study: 24791343
Drug: Metronidazole 1%
Normalized name: METRONIDAZOLE 1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 1% gel
Study: 11759644
Drug: Intravenous fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous fluconazole for six weeks
Study: 3422682
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (two chemotherapeutic regimens)
Study: 3422682
Drug: Chemotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy after recurrence
Study: 27306255
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (100 μg)
Study: 28368941
Drug: Continuous ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ropivacaine wound infusion (0.2%)
Study: 23418863
Drug: Lifestyle Wellness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle Wellness Program (LWP) - 12-week group intervention, one-hour weekly sessions discussing dietary choices, lifestyle, physical activity, and self-esteem.
Study: 21198573
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg frovatriptan
Study: 16565362
Drug: High-dose retinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose retinol (50,000 IU oral retinol for 30 days)
Study: 2629642
Drug: Education programme
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education programme consisting of two packages of education with four weekly meetings
Study: 25655226
Drug: XR-NTX (injections)
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-NTX (injections)
Study: 22219100
Drug: Total cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total cholesterol treatment goal (< 4.5 mmol/L)
Study: 22219100
Drug: Triglycerides treatment
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglycerides treatment goal (< 1.7 mmol/L)
Study: 22219100
Drug: LDL cholesterol
Normalized name: LDL cholesterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL cholesterol treatment goal (< 2.6 mmol/L)
Study: 22219100
Drug: HDL cholesterol
Normalized name: HDL cholesterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDL cholesterol treatment goal (> 1.0 mmol/L in men and > 1.3 mmol/L in women)
Study: 22219100
Drug: Meeting three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meeting three treatment goals (HbA1c, BP and cholesterol)
Study: 22219100
Drug: Meeting two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meeting two out of three treatment goals
Study: 22219100
Drug: Meeting only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meeting only one out of three treatment goals
Study: 19805643
Drug: Aspirin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin at bedtime
Study: 19805643
Drug: Aspirin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin at awakening
Study: 15542159
Drug: dl-alpha tocopheryl
Normalized name: DL-alpha tocopheryl acetate
DrugBank: DL-alpha tocopheryl acetate (DB14477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl-alpha tocopheryl acetate 500 mg twice a day orally plus pentoxifylline 400 mg twice a day orally
Study: 7969965
Drug: Selegiline 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 40 mg
Study: 3583073
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine at 1800 h
Study: 3583073
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine at 2200 h
Study: 24245491
Drug: Integrated intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated intervention (cognitive behavioral therapy) for alcohol, anxiety, and/or depression
Study: 16611342
Drug: Early CsA‐ME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early CsA‐ME (8 mg/kg/day starting on day 0)
Study: 16611342
Drug: Delayed CsA‐ME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed CsA‐ME (8 mg/kg/day starting on day 6)
Study: 10755246
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 mg bd for 7 days)
Study: 10755246
Drug: Trimethoprim‐sulphamethoxazole (TMPSMX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim‐sulphamethoxazole (TMPSMX; 160‐800 mg bd) or alternative therapy
Study: 8610430
Drug: High-dose fluconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fluconazole (400 mg/day)
Study: 22776066
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy intervention (3 months intervention from an occupational therapist)
Study: 15670980
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus high dose multiple antioxidants (ascorbic acid 6100 mg/day, dl-alpha-tocopherol 1050 mg/day, beta-carotene 60 mg/day)
Study: 25481791
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (paclitaxel and carboplatin)
Study: 27716152
Drug: Low-dose carvedilol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose carvedilol (maximum dose: 12.5 mg/day)
Study: 27716152
Drug: Low-dose carvedilol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose carvedilol
Study: 17009838
Drug: Fluid group
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid group (Bronchicum Elixir S, 6 x 5 ml daily)
Study: 17009838
Drug: Drops group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drops group (Bronchcium Tropfen, 5 x 1 ml daily)
Study: 14759070
Drug: T4 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: T4 (100 microg daily)
Study: 14759070
Drug: T3 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: T3 (25 microg daily)
Study: 11072156
Drug: C-RT (cisplatinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-RT (cisplatinum 40 mg/m(2)/weekly + radiation therapy)
Study: 11072156
Drug: RT (radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT (radiation therapy alone)
Study: 1385010
Drug: Continuous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high-dose aprotinin (7 x 10(6) KIU)
Study: 1385010
Drug: Continuous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high-dose aprotinin
Study: 1385010
Drug: Continuous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high-dose aprotinin and Single bolus of aprotinin
Study: 27480757
Drug: 1 × 10(10) colony-forming
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 10(10) colony-forming units of Lactobacillus rhamnosus GG, twice daily
Study: 23431028
Drug: Ambulatory oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory oxygen (AO) 2 L/min from a portable oxygen concentrator
Study: 18251212
Drug: Fixed-combination tablet
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination tablet of an ACE inhibitor (perindopril) with a diuretic (indapamide) (4 mg/l,250 mg)
Study: 9010691
Drug: LIPO-PGE1 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIPO-PGE1 (50 micrograms bolus injection)
Study: 9010691
Drug: PGE1-cyclodextrin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1-cyclodextrin (60 micrograms infusion over 2 hours)
Study: 1739236
Drug: Acetazolamide, 250
Normalized name: AcetaZOLAMIDE, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide, 250 mg orally
Study: 6377891
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg with meals three times daily)
Study: 26611571
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and saffron
Study: 26611571
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and placebo
Study: 20013046
Drug: Treatment responder
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment responder status
Study: 16472588
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg/20 mg
Study: 16472588
Drug: Adalimumab 80
Normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 80 mg/40 mg
Study: 16472588
Drug: Adalimumab 160
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab 160 mg/80 mg
Study: 9604449
Drug: UVB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB plus 100 g of calcipotriol (50 micrograms/g) ointment per week
Study: 9604449
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment alone (100 g/week)
Study: 9604449
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (UVB plus calcipotriol)
Study: 2422467
Drug: tiapamil 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiapamil 1 mg/kg body weight